Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions

Vaccine

Volumn 31, Issue 50, 2013, Pages 6011-6021

  Cho, Bo Hyun ^a   Stoecker, Charles ^b   Link Gelles, Ruth ^a   Moore, Matthew R ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b TULANE UNIVERSITY   (United States)

Author keywords

Immunocompromised adults; Incremental cost effectiveness; PCV13

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RISK; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; ORGAN TRANSPLANTATION; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REPEATED DRUG DOSE; UNITED STATES; VACCINATION;

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE; 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; ABCS; ACTIVE BACTERIAL CORE SURVEILLANCE; END STAGE RENAL DISEASE; ESRD; IMMUNOCOMPROMISED ADULTS; INCREMENTAL COST-EFFECTIVENESS; INVASIVE PNEUMOCOCCAL DISEASE; IPD; PCV13; PCV7; PPSV23; QALY; QUALITY ADJUSTED LIFE YEAR;

ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MODELS, STATISTICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84887609740     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.024     Document Type: Article

References (49)

1. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:816-819. Centers for Disease Control and Prevention.
2. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
3. Cohen A.L., Harrison L.H., Farley M.M., Reingold A.L., Hadler J., Schaffner W., et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010, 24:2253-2262.
4. Sisk J.E., Riegelman R.K. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Int Med 1986, 104:79-86.
5. Simberkoff M.S., Cross A.P., Al-Ibrahim M., Baltch A.L., Geiseler P.J., Nadler J., et al. Efficacy of pneumococcal vaccine in high-risk patients. N Engl J Med 1986, 315:1318-1327.
6. French N., Gilks C.F., Mujugira A., Fasching C., O'Brien J., Janoff E.N. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. AIDS 1998, 1998.
7. Palisade Corporation. @Risk 5.7. Newfield, NY2011.
8. Centers for disease control and prevention. HIV Surveill Rep 2010, 22.
9. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2009 Incidence and Mortality Web-based Report 2013, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta.
10. Health Resources and Services Administration, U.S. Department of Health & Human Services. Organ Procurement and Transport Network; 2012.
11. U. S Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
12. Schackman B.R., Gebo K.A., Walensky R.P., Losina E., Muccio T., Sax P.E., et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006, 44:990-997.
13. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying) - Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission.
14. Arias E. United States Life Tables, 2006. Natl Vital Statist Rep 2010, 58:1-40.
15. Active Bacterial Core Surveillance (ABCs) program. Centers for Disease Control and Prevention; unpublished data; September, 2011.
16. Weinberger D.M., Simonsen L., Jordan R., Steiner C., Miller M., Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 2012, 205:458-465.
17. National Center for Health Statistics. National Health Interview Survey. 1957-present. Public-use data file and documentation.
18. Teshale E.H., Hanson D., Flannery B., Phares C., Wolfe M., Schuchat A., et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 2008, 2008.
19. Guo H., Liu J., Collins A.J., Foley R.N. Pneumonia in incident dialysis patients-the United States Renal Data System. Nephrol Dial Transplant 2008, 23:680-686.
20. HCUP Nationwide Inpatient Sample (NIS). In: Quality AfHRa, editor. Healthcare Cost and Utilization Project (HCUP). Rockville, MD.
21. Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pnuemococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 2010, 59:1-18. Centers for Disease Control and Prevention.
22. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000, 355:2106-2111.
23. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362:812-822.
24. Girndt M., Sester M., Sester U., Kaul H., Köhler H. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001, 59:1382-1389.
25. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-1348.
26. Dworkin M.S., Ward J.W., Hanson D.L., Jones J.L., Kaplan J.E. Adult and adolescent spectrum of HIV disease project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001, 32:794-800.
27. Lu P., Nuorti J.P. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009. Am J Epidemiol 2012, 175:827-837.
28. Adult vaccination coverage-United States, 2010. MMWR Morb Mortal Wkly Rep 2012, 61:66-72. Centers for Disease Control and Prevention.
29. Truven Health Analytics MarketScan Database. Ann Arbor; 1994-2010.
30. BDIPharma. HCPCS Codes & Medicare Payment; 2012.
31. Deuson R.R., Hoekstra E.J., Sedjo R., Bakker G., Melinkovich P., Daeke D., et al. The Denver school-based adolescent Hepatitis B vaccination program: a cost analysis with risk simulation. Am J Public Health 1999, 89:1722-1727.
32. Maciosek M.V., Solberg L.I., Coffield A.B., Edwards N.M., Goodman M.J. Influenza vaccination: health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006, 31:72-79.
33. Bureau of Labor Statistics. Consumer Price Index-All Urban Consumers; 2012.
34. Khoie T, Tiernan R, deVore N. Prevnar 13™ (PCV13): Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein); 2011.
35. Winston WL. Simulation Modeling Using @Risk: Brooks/Cole-Duxbury; 2001.
36. Weycker D., Strutton D., Edelsberg J., Sato R., Jackson L.A. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010, 28:4955-4960.
37. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47:1329-1338.
38. RozenBaum M.H., van Hoek A., Fleming D., Trotter C.L., Miller E., Edmunds W.J. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012, 345:e6879.
39. Smith K.J., Wateska A.R., Nowalk M.P., Raymund M., Nuorti J.P., Zimmerman R.K. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012, 307:804-812.
40. Shapiro E.D. Prevention of Pneumococcal infection with vaccines. JAMA 2012, 307:847-849.
41. Crum-Cianflone N.F., Hullsiek K.H., Roediger M., Ganesan A., Patel S., Landrum M.L., et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010, 202:1114-1125.
42. Breiman R.F., Keller D.W., Phelan M.A., Sniadack D.H., Stephens D.S., Rimland D., et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633-2638.
43. Peñaranda M., Falco V., Payeras A., Jordano Q., Curran A., Pareja A., et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007, 45:e82-e87.
44. Tengs T.O., Lin T.H. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 2002, 22:475-481.
45. Gold M.R., Franks P., McCoy K.I., Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36:778-792.
46. Åberg F., Mäklin S., Räsänen P., Roine R.P., Sintonen H., Koivusalo A-M., et al. Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score. Liver Transplantat 2011, 17:1333-1343.
47. Hornberger J.C., Best J.H., LPG. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example. Med Decis Making 1997, 17:363-372.
48. Rubin J.L., McGarry L.J., Strutton D.R., Klugman K.P., Pelton S.I., Gilmore K.E., et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28:7634-7643.
49. Farnum N.R., Stanton L.W. Some results concerning the estimation of Beta distribution parameters in PERT. J Opl Res Soc 1987, 38:287-290.